Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.

Astolfi A, Vendemini F, Urbini M, Melchionda F, Masetti R, Franzoni M, Libri V, Serravalle S, Togni M, Paone G, Montemurro L, Bressanin D, Chiarini F, Martelli AM, Tonelli R, Pession A.

Oncotarget. 2014 Jan 15;5(1):120-30.

2.

NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.

Kusy S, Gerby B, Goardon N, Gault N, Ferri F, Gérard D, Armstrong F, Ballerini P, Cayuela JM, Baruchel A, Pflumio F, Roméo PH.

J Exp Med. 2010 Sep 27;207(10):2141-56. doi: 10.1084/jem.20100745. Epub 2010 Sep 20.

3.

The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.

Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, Brand M, Gutierrez A, Kelliher MA, Jamieson CH, von Boehmer H, Young RA, Look AT.

J Exp Med. 2013 Jul 29;210(8):1545-57. doi: 10.1084/jem.20122516. Epub 2013 Jul 15.

4.

Aberrant TAL1 activation is mediated by an interchromosomal interaction in human T-cell acute lymphoblastic leukemia.

Patel B, Kang Y, Cui K, Litt M, Riberio MS, Deng C, Salz T, Casada S, Fu X, Qiu Y, Zhao K, Huang S.

Leukemia. 2014 Feb;28(2):349-61. doi: 10.1038/leu.2013.158. Epub 2013 May 23.

PMID:
23698277
5.

UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia.

Benyoucef A, Palii CG, Wang C, Porter CJ, Chu A, Dai F, Tremblay V, Rakopoulos P, Singh K, Huang S, Pflumio F, Hébert J, Couture JF, Perkins TJ, Ge K, Dilworth FJ, Brand M.

Genes Dev. 2016 Mar 1;30(5):508-21. doi: 10.1101/gad.276790.115.

PMID:
26944678
6.

Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia.

Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, Ma W, Tatarek J, Ahn Y, Kelliher MA, Jamieson CH, Staudt LM, Young RA, Look AT.

Cancer Cell. 2012 Aug 14;22(2):209-21. doi: 10.1016/j.ccr.2012.06.007.

7.

Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.

McCormack MP, Shields BJ, Jackson JT, Nasa C, Shi W, Slater NJ, Tremblay CS, Rabbitts TH, Curtis DJ.

Blood. 2013 Sep 19;122(12):2093-103. doi: 10.1182/blood-2012-09-458570. Epub 2013 Aug 7.

8.

LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.

Smith S, Tripathi R, Goodings C, Cleveland S, Mathias E, Hardaway JA, Elliott N, Yi Y, Chen X, Downing J, Mullighan C, Swing DA, Tessarollo L, Li L, Love P, Jenkins NA, Copeland NG, Thompson MA, Du Y, Davé UP.

PLoS One. 2014 Jan 21;9(1):e85883. doi: 10.1371/journal.pone.0085883. eCollection 2014.

9.

Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines.

Nagel S, Venturini L, Meyer C, Kaufmann M, Scherr M, Drexler HG, MacLeod RA.

Leuk Res. 2010 Apr;34(4):521-8. doi: 10.1016/j.leukres.2009.06.020. Epub 2009 Jul 15.

PMID:
19608273
10.

ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.

Thoms JA, Birger Y, Foster S, Knezevic K, Kirschenbaum Y, Chandrakanthan V, Jonquieres G, Spensberger D, Wong JW, Oram SH, Kinston SJ, Groner Y, Lock R, MacKenzie KL, Göttgens B, Izraeli S, Pimanda JE.

Blood. 2011 Jun 30;117(26):7079-89. doi: 10.1182/blood-2010-12-317990. Epub 2011 May 2.

11.

Repressed BMP signaling reactivates NKL homeobox gene MSX1 in a T-ALL subset.

Nagel S, Ehrentraut S, Meyer C, Kaufmann M, Drexler HG, MacLeod RA.

Leuk Lymphoma. 2015 Feb;56(2):480-91. doi: 10.3109/10428194.2014.924119. Epub 2014 Jun 12.

PMID:
24844359
12.

Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.

Kuang SQ, Fang Z, Zweidler-McKay PA, Yang H, Wei Y, Gonzalez-Cervantes EA, Boumber Y, Garcia-Manero G.

PLoS One. 2013 Apr 26;8(4):e61807. doi: 10.1371/journal.pone.0061807. Print 2013.

13.

Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.

Nagel S, Venturini L, Meyer C, Kaufmann M, Scherr M, Drexler HG, Macleod RA.

Leuk Lymphoma. 2011 Feb;52(2):290-7. doi: 10.3109/10428194.2010.537003. Epub 2011 Jan 24.

PMID:
21261500
14.

MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.

Huang R, Cheung NK, Vider J, Cheung IY, Gerald WL, Tickoo SK, Holland EC, Blasberg RG.

FASEB J. 2011 Dec;25(12):4138-49. doi: 10.1096/fj.11-185033. Epub 2011 Aug 19.

15.

Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia.

Correia NC, Durinck K, Leite AP, Ongenaert M, Rondou P, Speleman F, Enguita FJ, Barata JT.

Leukemia. 2013 Jul;27(7):1603-6. doi: 10.1038/leu.2013.63. Epub 2013 Mar 1. No abstract available.

PMID:
23448994
16.

Site- and allele-specific polycomb dysregulation in T-cell leukaemia.

Navarro JM, Touzart A, Pradel LC, Loosveld M, Koubi M, Fenouil R, Le Noir S, Maqbool MA, Morgado E, Gregoire C, Jaeger S, Mamessier E, Pignon C, Hacein-Bey-Abina S, Malissen B, Gut M, Gut IG, Dombret H, Macintyre EA, Howe SJ, Gaspar HB, Thrasher AJ, Ifrah N, Payet-Bornet D, Duprez E, Andrau JC, Asnafi V, Nadel B.

Nat Commun. 2015 Jan 23;6:6094. doi: 10.1038/ncomms7094.

17.

MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia.

Mets E, Van der Meulen J, Van Peer G, Boice M, Mestdagh P, Van de Walle I, Lammens T, Goossens S, De Moerloose B, Benoit Y, Van Roy N, Clappier E, Poppe B, Vandesompele J, Wendel HG, Taghon T, Rondou P, Soulier J, Van Vlierberghe P, Speleman F.

Leukemia. 2015 Apr;29(4):798-806. doi: 10.1038/leu.2014.276. Epub 2014 Sep 18.

18.

TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells.

Cardoso BA, de Almeida SF, Laranjeira AB, Carmo-Fonseca M, Yunes JA, Coffer PJ, Barata JT.

Leukemia. 2011 Oct;25(10):1578-86. doi: 10.1038/leu.2011.140. Epub 2011 Jun 7.

PMID:
21647153
19.

Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements.

Homminga I, Vuerhard MJ, Langerak AW, Buijs-Gladdines J, Pieters R, Meijerink JP.

Haematologica. 2012 Feb;97(2):258-61. doi: 10.3324/haematol.2011.051722. Epub 2011 Nov 4.

20.

NFKB1 is a direct target of the TAL1 oncoprotein in human T leukemia cells.

Chang PY, Draheim K, Kelliher MA, Miyamoto S.

Cancer Res. 2006 Jun 15;66(12):6008-13.

Items per page

Supplemental Content

Write to the Help Desk